The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48 000 initiators of statin therapy
- 8 June 2006
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 15 (7) , 444-453
- https://doi.org/10.1002/pds.1281
Abstract
Purpose The purpose of this study was to compare incidence rates of hospitalization associated with rhabdomyolysis, myopathy, renal, or hepatic dysfunction, and of in‐hospital death, between initiators of rosuvastatin and other statins. Methods This was a matched cohort study of statin initiators from the administrative database of a large health insurer in the US, during the first 6 months of rosuvastatin availability with up to 18 months of follow‐up. All outcome events were verified by medical record review. Incidence rates, risk ratios, and associated 95% confidence intervals were estimated. Results From an initial pool of 12 217, 11 249 eligible rosuvastatin initiators were matched to 37 282 initiators of other statins. The incidence rate (IR) per 1000 person‐years for rhabdomyolysis was 0.10 [0.00, 0.55] for rosuvastatin initiators (n = 1) and 0.06 [0.01, 0.22] for other statin initiators (n = 2), for a hazard ratio (HR) of 1.98 [0.18, 21.90]. The IR for myopathy was 0.20 [0.02, 0.71] for rosuvastatin initiators (n = 2) and 0.00 [0.00, 0.09] for other statin initiators (n = 0). The IR for renal dysfunction was 1.18 [0.61, 2.06] for rosuvastatin initiators (n = 12) and 1.26 [0.91, 1.71] for other statin initiators (n = 42), for a HR of 0.90 [0.47, 1.73]. The IR for hepatic dysfunction was 0.20 (0.02, 0.71) for rosuvastatin initiators (n = 2) and 0.24 (0.10, 0.47) for other statin initiators (n = 8), for a HR of 0.87 (0.18, 4.14). Conclusions This study found no difference between rosuvastatin and the other statins in the incidence of hospitalizations associated with renal or hepatic events, or death. The absolute incidence rates of rhabdomyolysis and myopathy were reassuringly low among all statin initiators but remain too small for firm conclusions to be drawn on any difference between the statins. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 18 references indexed in Scilit:
- Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering DrugsJAMA, 2004
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004
- Intensive Statin Therapy — A Sea Change in Cardiovascular PreventionNew England Journal of Medicine, 2004
- Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemiaExpert Review of Cardiovascular Therapy, 2003
- Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the heart protection study on standards of efficacyand safetyThe American Journal of Cardiology, 2003
- Pharmacologic characteristics of statinsClinical Cardiology, 2003
- Cerivastatin and Reports of Fatal RhabdomyolysisNew England Journal of Medicine, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.The American Journal of Cardiology, 2001